Mora, J.; Castañeda, A.; Colombo, M.C.; Gorostegui, M.; Gomez, F.; Mañe, S.; Santa-Maria, V.; Garraus, M.; Macias, N.; Perez-Jaume, S.;
et al. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers 2021, 13, 1264.
https://doi.org/10.3390/cancers13061264
AMA Style
Mora J, Castañeda A, Colombo MC, Gorostegui M, Gomez F, Mañe S, Santa-Maria V, Garraus M, Macias N, Perez-Jaume S,
et al. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers. 2021; 13(6):1264.
https://doi.org/10.3390/cancers13061264
Chicago/Turabian Style
Mora, Jaume, Alicia Castañeda, Maria Cecilia Colombo, Maite Gorostegui, Fernando Gomez, Salvador Mañe, Vicente Santa-Maria, Moira Garraus, Napoleon Macias, Sara Perez-Jaume,
and et al. 2021. "Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma" Cancers 13, no. 6: 1264.
https://doi.org/10.3390/cancers13061264
APA Style
Mora, J., Castañeda, A., Colombo, M. C., Gorostegui, M., Gomez, F., Mañe, S., Santa-Maria, V., Garraus, M., Macias, N., Perez-Jaume, S., Muñoz, O., Muñoz, J. P., Barber, I., & Suñol, M.
(2021). Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers, 13(6), 1264.
https://doi.org/10.3390/cancers13061264